08:04 AM EDT, 09/16/2025 (MT Newswires) -- Covalon Technologies ( CVALF ) Tuesday said a peer-reviewed clinical study found its VALGuard vascular-access line guard significantly reduced central line-associated bloodstream infections (CLABSIs), including a sustained period of zero CLABSIs in the Pediatric Critical Care Unit at the Children's Hospital at Montefiore in the U.S.

The study appears in the Journal of the Association for Vascular Access (JAVA). A scientific poster based on the findings was chosen as one of only four to be presented from the podium during a pediatric-focused session at the Association for Vascular Access annual scientific meeting in September, Covalon ( CVALF ) said.

VALGuard is a transparent, single-use barrier device that covers IV line connections and catheter hubs to protect against gross contamination. CLABSIs are among the most serious and costly hospital-acquired infections, largely preventable and a top priority for health-system infection-control efforts, the company added.